NK CellTech develops synthetic immunology technologies to engineer and manipulate natural killer (NK) cells for targeted cancer therapies. By creating customized NK cells, the company aims to provide tumor patients with effective treatments that minimize side effects and meet specific clinical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer therapies often lack specificity, leading to significant side effects and limited efficacy, particularly in solid tumors. Traditional methods of manipulating natural killer (NK) cells for cancer treatment face challenges in achieving precise targeting and sustained activity within the tumor microenvironment.
Solution
NK CellTech develops synthetic immunology technologies to engineer and enhance natural killer (NK) cells for targeted cancer immunotherapy. Their ABCDE-NK® strategy employs gene manipulation to create customized NK cells with enhanced tumor recognition, controlled activation, and improved persistence. These engineered NK cells are designed to address unmet clinical needs by providing more effective and targeted treatments for patients with solid tumors, while minimizing off-target effects. The company's approach aims to rebuild innate immunity to eliminate tumors by quantifying, controlling, and optimizing NK cell function through synthetic biology.
Target Audience
The primary target audience includes cancer patients with solid tumors, oncologists, and clinical researchers seeking more effective and targeted immunotherapies with reduced side effects.
Features
- ABCDE-NK® technology platform for engineering NK cells with synthetic logic circuits, feedback switches, and intelligent control systems
- Precision targeting of tumor cells through genetic modification of NK cell receptors
- Enhanced NK cell activity and persistence within the tumor microenvironment
- Development of PBMC-NK cells for allogeneic cell therapy
- Pipeline of NK cell therapies targeting various solid tumors, including NK-010, NK-042, NK-043, NK-062, NK-063, NK-081, NK-082, and NK-091
- Full human mice models for preclinical testing and validation of NK cell therapies